CYP3A诱导可预测P-糖蛋白诱导:第2部分——预测利福布汀或卡马西平降低底物暴露
本研究在健康受试者中给予索磷布韦和六探针药物组合,比较利福布汀300 mg每日一次或卡马西平300 mg每日两次前后,利用观察到的CYP3A诱导预测P-gp、CYP2C9诱导及索磷布韦暴露下降,结果显示P-gp、CYP2C9诱导和索磷布韦暴露下降被成功预测,但卡马西平对OATP的诱导被低估,可能与其额外的非PXR激动作用有关。
要点
- PXR激动剂对CYP3A的诱导程度可用于推断其他主要受PXR调控的P450酶/转运体的诱导风险。
- 利福布汀或卡马西平对P-gp和CYP2C9的诱导及索磷布韦暴露下降可由CYP3A诱导成功预测。
- 卡马西平对OATP的诱导被低估,可能因其具有额外的非PXR激动作用。
核心结论
- PXR激动剂对CYP3A的诱导效应可用于预测其他主要受PXR调控的P450酶/转运体的诱导风险,从而在新药研发中优先安排针对性DDI评估。
研究设计与样本
- 健康受试者先后接受索磷布韦和六探针药物组合,并在利福布汀300 mg每日一次或卡马西平300 mg每日两次前后进行自身对照比较。
主要发现
- 利福布汀或卡马西平对P-gp、CYP2C9的诱导以及索磷布韦暴露下降均被观察到的CYP3A诱导成功预测。
- 卡马西平对OATP的诱导被低估,可能与其报道的额外非PXR激动作用有关。
关键数值与推荐
- 利福布汀300 mg每日一次或卡马西平300 mg每日两次给药后,基于CYP3A诱导预测P-gp、CYP2C9诱导及索磷布韦暴露下降。
临床怎么用
- 临床药学中可参考CYP3A诱导强度预判P-gp等转运体介导的DDI风险,但需注意卡马西平等非单纯PXR激动剂可能低估OATP诱导。
局限性
- 卡马西平对OATP的诱导被低估,提示仅基于PXR激动预测可能不适用于具有额外非PXR激动作用的药物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rifampin demonstrated dose-dependent relative induction between cytochrome P (CYP)3A and P-glycoprotein (P-gp), organic anion transporting polypeptides (OATPs), or CYP2C9; P-gp, OATP, and CYP2C9 induction was one drug-drug interaction (DDI) category lower than that observed for CYP3A across a wide range of pregnane X receptor (PXR) agonism. The objective of this study was to determine if these relationships could be utilized to predict transporter induction by other CYP3A inducers (rifabutin and carbamazepine) and of another P-gp substrate, sofosbuvir. Healthy subjects received sofosbuvir and a six-probe drug cassette before and after 300 mg q.d. rifabutin or 300 mg b.i.d. carbamazepine. Induction of P-gp, CYP2C9, and decreased sofosbuvir exposure were successfully predicted by observed CYP3A induction. Carbamazepine induction of OATP was underpredicted, likely due to reported additional non-PXR agonism. The results demonstrate that the effect of a PXR agonist on CYP3A can be leveraged to inform on induction liability for other primarily PXR-regulated P450s/transporters, allowing for prioritization of targeted DDI assessments during new drug development.
引用
- Lutz JD, Kirby BJ, Wang L, et al. Cytochrome P450 3A Induction Predicts P-glycoprotein Induction; Part 2: Prediction of Decreased Substrate Exposure After Rifabutin or Carbamazepine. Clin Pharmacol Ther. 2018. PMID: 29569712. doi:10.1002/cpt.1072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。